In response to President Donald Trump's demands for reshoring manufacturing, several major US pharmaceutical firms, originally connected to Ireland, have pledged to open new production facilities in the United States. This move comes at a time when Irish business leaders are expressing concern about potential trade wars affecting investment decisions. As a result, many plans for expansion seem to be on hold, creating uncertainty in Ireland's business landscape while US firms strategize for increased production stateside.
Several US pharma firms are reaffirming their commitment to opening new production facilities in America, influenced by the demands for reshoring manufacturing.
Investment decisions by Irish leaders are being impacted by looming threats of a trade war, causing delays in strategy implementations.
Collection
[
|
...
]